Percutaneous coronary intervention: basic principles and guidelines: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (2 intermediate revisions by one other user not shown) | |||
| Line 18: | Line 18: | ||
===Pre-procedural Considerations=== | ===Pre-procedural Considerations=== | ||
[[Percutaneous coronary intervention contrast-induced acute kidney injury|Contrast-Induced Acute Kidney Injury]] | [[Percutaneous coronary intervention anaphylactoid reactions|Anaphylactoid Reactions]] | [[Percutaneous coronary intervention statin treatment|Statin Treatment]] | [[Percutaneous coronary intervention bleeding risk|Bleeding Risk]] | [[Percutaneous coronary intervention role of onsite surgical backup|Role of Onsite Surgical Backup]] | |||
===Procedural Considerations=== | ===Procedural Considerations=== | ||
| Line 30: | Line 30: | ||
*[[Percutaneous coronary intervention prior coronary bypass surgery|Prior Coronary Bypass Surgery]] | *[[Percutaneous coronary intervention prior coronary bypass surgery|Prior Coronary Bypass Surgery]] | ||
*[[Percutaneous coronary intervention revascularization before non-cardiac surgery|Revascularization Before Non-cardiac Surgery]] | *[[Percutaneous coronary intervention revascularization before non-cardiac surgery|Revascularization Before Non-cardiac Surgery]] | ||
*'''Adjunctive Diagnostic Devices''': [[Percutaneous coronary intervention fractional flow reserve|Fractional Flow Reserve]] | [[Percutaneous coronary intervention intravascular ultrasound|Intravascular Ultrasound]] | *'''Adjunctive Diagnostic Devices''': [[Percutaneous coronary intervention fractional flow reserve|Fractional Flow Reserve]] | [[Percutaneous coronary intervention intravascular ultrasound|Intravascular Ultrasound]] | ||
*'''Adjunctive Therapeutic Devices''': [[Percutaneous coronary intervention coronary atherectomy|Coronary Atherectomy]] | [[Percutaneous coronary intervention thrombectomy|Thrombectomy]] | [[Percutaneous coronary intervention laser angioplasty|Laser Angioplasty]] | [[Percutaneous coronary intervention cutting balloon angioplasty|Cutting Balloon Angioplasty]] | [[Percutaneous coronary intervention embolic protection devices|Embolic Protection Devices]] | *'''Adjunctive Therapeutic Devices''': [[Percutaneous coronary intervention coronary atherectomy|Coronary Atherectomy]] | [[Percutaneous coronary intervention thrombectomy|Thrombectomy]] | [[Percutaneous coronary intervention laser angioplasty|Laser Angioplasty]] | [[Percutaneous coronary intervention cutting balloon angioplasty|Cutting Balloon Angioplasty]] | [[Percutaneous coronary intervention embolic protection devices|Embolic Protection Devices]] | ||
| Line 36: | Line 35: | ||
*Antiplatelet therapy: | *Antiplatelet therapy: | ||
**[[Percutaneous coronary intervention oral antiplatelet therapy|Oral Antiplatelet Therapy]] | **[[Percutaneous coronary intervention oral antiplatelet therapy|Oral Antiplatelet Therapy]] | ||
** Glycoprotein IIb/IIIa Receptor Antagonists | |||
**Intravenous Antiplatelet therapy: [[Percutaneous coronary intervention ST-elevation myocardial infarction (STEMI)|STEMI]] | [[Percutaneous coronary intervention unstable angina / non-ST elevation myocardial infarction (UA/NSTEMI)|UA/NSTEMI]] | [[Percutaneous coronary intervention sudden ischemia heart disease (SIHD)|SIHD]] | **Intravenous Antiplatelet therapy: [[Percutaneous coronary intervention ST-elevation myocardial infarction (STEMI)|STEMI]] | [[Percutaneous coronary intervention unstable angina / non-ST elevation myocardial infarction (UA/NSTEMI)|UA/NSTEMI]] | [[Percutaneous coronary intervention sudden ischemia heart disease (SIHD)|SIHD]] | ||
*'''Anticoagulant Therapy''': [[Percutaneous coronary intervention use of parenteral anticoagulants during PCI|Parenteral Anticoagulants During PCI]] | [[Percutaneous coronary intervention unfractionated heparin|Unfractionated Heparin]] | [[Percutaneous coronary intervention enoxaparin|Enoxaparin]] | [[Percutaneous coronary intervention bivalirudin and argatoban|Bivalirudin and Argatroban]] | [[Percutaneous coronary intervention fondaparinux|Fondaparinux]] | [[Percutaneous coronary intervention no-reflow pharmacological therapies|No-Reflow Pharmacological Therapies]] | *'''Anticoagulant Therapy''': [[Percutaneous coronary intervention use of parenteral anticoagulants during PCI|Parenteral Anticoagulants During PCI]] | [[Percutaneous coronary intervention unfractionated heparin|Unfractionated Heparin]] | [[Percutaneous coronary intervention enoxaparin|Enoxaparin]] | [[Percutaneous coronary intervention bivalirudin and argatoban|Bivalirudin and Argatroban]] | [[Percutaneous coronary intervention fondaparinux|Fondaparinux]] | [[Percutaneous coronary intervention no-reflow pharmacological therapies|No-Reflow Pharmacological Therapies]] | ||
Latest revision as of 17:55, 30 October 2012
|
Percutaneous Coronary Intervention Guidelines Microchapters |
|
PCI Approaches: |
|---|
|
CAD Revascularization: |
|
Pre-procedural Considerations: |
|
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
|
Quality and Performance Considerations: |
|
Percutaneous coronary intervention: basic principles and guidelines On the Web |
|
American Roentgen Ray Society Images of Percutaneous coronary intervention: basic principles and guidelines |
|
FDA on Percutaneous coronary intervention: basic principles and guidelines |
|
CDC on Percutaneous coronary intervention: basic principles and guidelines |
|
Percutaneous coronary intervention: basic principles and guidelines in the news |
|
Blogs on Percutaneous coronary intervention: basic principles and guidelines |
|
Directions to Hospitals Treating Percutaneous Coronary Intervention |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Lakshmi Gopalakrishnan, M.B.B.S. [2]
Synonyms and keywords: PCI; balloon angioplasty; percutaneous transluminal angioplasty
Overview
Guideline Recommendations
CAD Revascularization
Heart Team Approach to Revascularization Decisions | Left Main Coronary Artery Disease | Non-Left Main Coronary Artery Disease | Revascularization to Improve Symptoms | Dual Antiplatelet Therapy Compliance and Stent Thrombosis | Hybrid Coronary Revascularization
Pre-procedural Considerations
Contrast-Induced Acute Kidney Injury | Anaphylactoid Reactions | Statin Treatment | Bleeding Risk | Role of Onsite Surgical Backup
Procedural Considerations
- Vascular Access
- PCI in Specific Clinical Situations:
- Asymptomatic Ischemia or CCS Class I or II Angina
- CCS Class III Angina
- Unstable Angina/Non–ST-Elevation Myocardial Infarction
- ST-Elevation Myocardial Infarction: General and Specific Considerations | Coronary Angiography Strategies in STEMI | Primary PCI of the Infarct Artery | Delayed or Elective PCI in patients with STEMI | Fibrinolytic-Ineligible Patients | Facilitated PCI | Rescue PCI | After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
- Cardiogenic Shock
- Prior Coronary Bypass Surgery
- Revascularization Before Non-cardiac Surgery
- Adjunctive Diagnostic Devices: Fractional Flow Reserve | Intravascular Ultrasound
- Adjunctive Therapeutic Devices: Coronary Atherectomy | Thrombectomy | Laser Angioplasty | Cutting Balloon Angioplasty | Embolic Protection Devices
- Percutaneous Hemodynamic Support Devices
- Antiplatelet therapy:
- Oral Antiplatelet Therapy
- Glycoprotein IIb/IIIa Receptor Antagonists
- Intravenous Antiplatelet therapy: STEMI | UA/NSTEMI | SIHD
- Anticoagulant Therapy: Parenteral Anticoagulants During PCI | Unfractionated Heparin | Enoxaparin | Bivalirudin and Argatroban | Fondaparinux | No-Reflow Pharmacological Therapies
- PCI in Specific Anatomic Situations: Chronic Total Occlusions | Saphenous Vein Grafts | Bifurcation Lesions | Aorto-Ostial Stenoses | Calcified Lesions
- PCI in Specific Patient Populations: Chronic Kidney Disease
- Peri-procedural Myocardial Infarction Assessment
- Vascular Closure Devices
Post-Procedural Considerations
- Post-procedural Antiplatelet Therapy
- Proton Pump Inhibitors and Antiplatelet Therapy
- Clopidogrel Genetic Testing
- Platelet Function Testing
- Restenosis
- Exercise Testing
- Cardiac Rehabilitation
Quality and Performance Considerations
Quality and Performance | Certification and Maintenance of Certification | Operator and Institutional Competency and Volume